EN DE
Watch GETS Global Bhd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

GETS Global Bhd (5079) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of GETS Global Bhd stock MYR 0.16, price MYR 0.13, upside +23.1%, quality 26 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare MY · ISIN MYL5079OO008

GG GETS Global Bhd logo Thin data Nov 7, 2026

GETS Global Bhd

5079 · KLSE
Speculative

The stock costs 19% less than our calculation considers fair.

Fair value 0.1600 MYR · Undervalued
Low debt
Revenue last quarter +74% vs. a year ago.
Mixed Growth (revenue 5y +28.2 %/yr in MYR)
Mixed vs. peers (4/10)
Quality 26/100
Loss-making · -81.7% net margin (TTM)
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
⚠ Small free float
Watch GETS Global Bhd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

2.71 MYR 0.0900 MYR Fair Value 0.1600 MYR Feb 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range 0.0900 MYR – 2.71 MYR · fair‑value band 0.1200 MYR – 0.2400 MYR · the 0.1300 MYR price screens below the 0.1600 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow GETS Global Bhd in your weekly email

Every Wednesday you see whether GETS Global Bhd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

One Glove Group Berhad, an investment holding company, manufactures, markets, and sells examination gloves and other related activities in Malaysia, Japan, Germany, the United States, India, and internationally.

Show moreShow less

The company offers powder-free nitrile butadiene rubber medical examination and industrial gloves. It also sells fresh fruit bunches. The company was formerly known as GETS Global Berhad and changed its name to One Glove Group Berhad in July 2022.

One Glove Group Berhad was incorporated in 2002 and is based in Kamunting, Malaysia.

Stock analysis

GETS Global Bhd (5079) currently trades at 0.1300 MYR, while our model-based Fair Value estimate is 0.1600 MYR, implying the stock looks roughly 19% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: 0.1200 MYR (bear) to 0.2400 MYR (bull), the price of 0.1300 MYR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

GETS Global Bhd reported revenue of 39.5M MYR in FY2025 versus 11.4M MYR in FY2020, a compound +28.2%/yr. Reported net income was −39.1M MYR in FY2025.

Key figures

Market cap 75.8M MYR (≈ $18.7M) Micro · P/S ratio 1.80 · EPS (TTM) −0.0600 MYR · Net margin −81.7% · Return on equity −26.8% · Return on assets (EBIT) −7.5% (5-year average) · Operating margin −50.0% · Revenue (TTM) 45.4M MYR.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and 44% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 23%, 5079 screens cheaper than that median.

Fair Value models

Bear 0.1200 MYR Fair Value 0.1600 MYR Bull 0.2400 MYR
Price 0.1300 MYR · Upside +23.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 0.1200 MYR 0.1600 MYR 0.2400 MYR 54
All 1 models by family
Asset-Based
NCAV (Graham) 0.1200 MYR 0.1600 MYR 0.2400 MYR 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 32
Debt, balance sheet and risk of trouble
Investment 34
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 21
Distance to the 52-week high, does not count
New shares 65
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.2%
Start year 2020 (pandemic). Over 10 years: +1.2% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−171.8% (2020) → −82.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 5079, get fair value alerts →

Compare GETS Global Bhd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside +23.1% · Top 25%
Profitability
Return on assets −8.3% · Bottom 25%
Net margin (12 months) −81.7% · Bottom 25%
Operating margin (12 months) −50.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 73.7% · Top 25%
Balance sheet
Debt / equity 0.37× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 0.45× · Cheapest 25%
P/S (12 months) 1.67× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)64 · sector 25
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 30
HEALTH (low debt)82 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.27 +45% vs 5079
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs 5079
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs 5079
Medline Inc MDLN $39.64 $28.59 −28% vs 5079
Alcon Inc ALC CHF 61.30 CHF 34.06 −44% vs 5079
Becton, Dickinson and Company BDX $211.88 $97.80 −54% vs 5079
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs 5079
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs 5079
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs 5079
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs 5079

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

GETS Global Bhd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "GETS Global Bhd Fair Value". https://www.fairvalue-calculator.com/stock/5079

Frequently asked questions

Is GETS Global Bhd (5079) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 0.1600 MYR versus a price of 0.1300 MYR, about +23% upside (undervalued).
What is the fair value of 5079?
Our model-based fair value for GETS Global Bhd is 0.1600 MYR (as of Nov 7, 2026), built from audited fundamentals. The current price: 0.1300 MYR.
What is the quality score of 5079?
GETS Global Bhd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GETS Global Bhd (5079)?
Our model-based price target is the fair value of 0.1600 MYR (as of Nov 7, 2026) from 1 valuation models. Cautious scenario 0.1200 MYR, optimistic scenario 0.2400 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the GETS Global Bhd stock forecast for 2026?
Our models put fair value at 0.1600 MYR, about +23% upside versus a price of 0.1300 MYR (undervalued). Cautious scenario 0.1200 MYR, optimistic scenario 0.2400 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of GETS Global Bhd (5079)?
GETS Global Bhd reported trailing-twelve-month revenue of about 45.4M MYR (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of GETS Global Bhd (5079)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GETS Global Bhd it is 0.1600 MYR per share (as of Nov 7, 2026), against a price of 0.1300 MYR. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is GETS Global Bhd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 5079 trades below its calculated fair value: price 0.1300 MYR, fair value 0.1600 MYR, a gap of about +23% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 5079?
No. The price is what the market pays today (0.1300 MYR); the fair value is what the company's own numbers justify (0.1600 MYR). For GETS Global Bhd the two are 0.0300 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is GETS Global Bhd worth?
The market values GETS Global Bhd at about 75.8M MYR (market capitalisation, as of Nov 7, 2026). Per share that is 0.1300 MYR; our models calculate a fair value of 0.1600 MYR per share.
What do the bullish and bearish scenarios say about 5079?
Our models span a range for GETS Global Bhd: cautious scenario 0.1200 MYR, base 0.1600 MYR, optimistic 0.2400 MYR per share (as of Nov 7, 2026, price 0.1300 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of GETS Global Bhd (5079)?
Balance-sheet figures for GETS Global Bhd (as of Nov 7, 2026): return on equity −26.8%, debt of 0.37 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 5079 from its 52-week high?
GETS Global Bhd trades at 0.1300 MYR, about 26% below its 52-week high of 0.1750 MYR and 44% above the low of 0.0900 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1600 MYR is for.
Which stocks are comparable to GETS Global Bhd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GETS Global Bhd stock attractive at the current price?
The data as of Nov 7, 2026: price 0.1300 MYR, calculated fair value 0.1600 MYR (+23%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 5079 calculated?
We run GETS Global Bhd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 0.1600 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. GETS Global Bhd currently trades 19% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GETS Global Bhd (5079)?
The closing price on Nov 6, 2026 was 0.1300 MYR. Our model-based fair value is 0.1600 MYR, about +23% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GETS Global Bhd right now?
A fairly wide model range (0.1200 MYR to 0.2400 MYR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of GETS Global Bhd

How large is the market capitalisation of GETS Global Bhd (5079)?
The market capitalisation of GETS Global Bhd is 75.8M MYR (≈ $18.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GETS Global Bhd (5079)?
The price-to-sales ratio of GETS Global Bhd is 1.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GETS Global Bhd (5079)?
Earnings per share at GETS Global Bhd are −0.0600 MYR. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of GETS Global Bhd (5079)?
The net margin of GETS Global Bhd is −81.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GETS Global Bhd (5079)?
The return on equity (ROE) of GETS Global Bhd is −26.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GETS Global Bhd (5079)?
On an EBIT basis the return on assets of GETS Global Bhd is −7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GETS Global Bhd (5079)?
The operating margin of GETS Global Bhd is −50.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GETS Global Bhd (5079)?
Revenue at GETS Global Bhd is growing +73.7% versus a year earlier (3y avg +12.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does GETS Global Bhd (5079) generate?
The free cash flow of GETS Global Bhd is −14.0M MYR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does GETS Global Bhd (5079) carry?
The net debt of GETS Global Bhd is 65.9M MYR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch GETS Global Bhd in the live analysis

One click puts GETS Global Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.